Akcea Therapeutics Inc

Overview

Akcea Therapeutics Inc (Akcea Therapeutics), a subsidiary of Ionis Pharmaceuticals Inc, is a developes and commercializes RNA-targeted medicines to treat patients with rare diseases. The company pipeline product includes volanesorsen (WAYLIVRA) for the treatment of rare metabolic disorders including familial chylomicronemia syndrome (FCS); AKCEA-APO(a)-LRx to treat hyperlipoproteinemia; AKCEA-ANGPTL3-LRx for rare cardiovascular and metabolic diseases; AKCEA-APOCIII-LRx used to treat high triglycerides. It also develops AKCEA-TTR-LRx along with Ionis Pharmaceuticals to treat Transthyretin amyloidosis (ATTR). Akcea Therapeutics also markets TEGSEDI, an injection that treats the polyneuropathy. The company’s Antisense technology is based on synthetic nucleic acid sequences to interrupt the production of a specified protein by targeting the specific corresponding messenger RNA. Akcea Therapeutics is headquartered in Cambridge, Massachusetts, the US.
Key Stats
Address
9th Floor, 22 Boston Wharf Road, Boston, Massachusetts
Headquarters

United States of America

Contact

1 617 2070202

Website
akceatx.com
No of Employees

294

Industry

Pharmaceuticals and Healthcare

Peer Comparison

Key Parameters Akcea Therapeutics IncMerck & Co IncIntercept Pharmaceuticals IncAllysta Pharmaceuticals Inc
Key Information
Headquarters United States of America United States of America United States of America United States of America
Headquarter City Boston KENILWORTH NEW YORK Belmont
Headquarter State/Province Massachusetts New Jersey New York California
No. of Employees 294 74,000 498 -
Entity Type Private Public Public Private

Products & Services

Akcea Therapeutics is engaged in developing and commercializing of transformative drugs. Key products offered by the company include the following:

Products
  • Pipe lineProducts :
  • WAYLIVRA
  • Rare Metabolic Disorders
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
Brands
  • WAYLIVRA
  • TEGSEDI

Employees

Name Position Board Since Age Biography
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.

History

Year Event Description
2020 Contracts/Agreements In August, the company and Ionis Pharmaceuticals entered into an agreement, in which Ionis will…
2019 Contracts/Agreements In October, Akcea and Pfizer Inc entered into a worldwide exclusive licensing agreement for AKCEA-ANGPTL3-LRx,…
2018 Contracts/Agreements In August, Akcea Therapeutics entered into an agreement with PTC Therapeutics to commercialize its rare…
2017 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2017 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2015 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam

Locations


Akcea Therapeutics UK Ltd
Akcea Therapeutics Ireland Limited
Akcea Therapeutics Portugal, Unipessoal Lda
Akcea Therapeutics Spain Sl,

Deals

Number of Deals
Deal Value (US$ m)

Latest Deals

Announced Date Headline Deal Type Acquirers / Investors / Surviving Entity Issuer / partner / Target
31 Aug 2020 Ionis Pharma Acquires Remaining 24% Stake in Akcea Therapeutics Acquisition Ionis Pharmaceuticals Inc Akcea Therapeutics Inc
18 Dec 2019 Akcea Therapeutics and Ionis Pharma Retains Rights to AKCEA-APOCIII-LRx from Novartis Licensing Agreement Ionis Pharmaceuticals Inc; Akcea Therapeutics Inc Novartis AG
07 Oct 2019 Pfizer Enters into Licensing Agreement with Akcea Therapeutics and Ionis Pharma Licensing Agreement Pfizer Inc Ionis Pharmaceuticals Inc; Akcea Therapeutics Inc
03 May 2019 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
22 Feb 2019 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
31 Dec 2018 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit